Dear Friend;
Attached is today’s press release. Here is some background:
1. We announced April 11, 2024, a private placement of a convertible debenture financing for up to $3M at $0.25.
2. Today we announce the first tranche of that financing with gross proceeds of $941,000 with insider participation of $355,000 or 38% of this tranche. Thank you to those you who invested.
3. In addition, insiders have purchased 360,000 shares ninth market since the announcement of the private placement.
4. Obviously, we see a bright future for the company as our new sales approach of doing workshops at major conferences is working well.
5. We had 97 clinicians register for our workshops at the APEC congress in Europe last week.
6. We have a number of larger investors completing their due diligence and we expect to complete the financing by the end of May with additional insider participation.
7. If you would like to invest in the convertible debenture which has an interest rate of 10% per annum and a bonus 1/2 warrant for early exercise, then please send me an email or text and I will confirm the allocation.
Thank you for your ongoing support and interest as the Company continues to improve cardiac diagnostics for everyone, everywhere, and especially for children born with heart defects.
Regards,
Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.